Table 3

Conditional and marginal joint effects of treatment and weight status on time-to-management failure

TreatmentWeight statusEvents/Visit-weeks (n)Average HR (95% CI)*
LTRA monotherapyBMI >80th percentile12/5631.09 (0.60 to 2.00)1.14 (0.61 to 2.13)
BMI ≤80th percentile16/4701.69 (1.00 to 2.88)1.72 (1.01 to 2.93)
Low-dose ICS monotherapyBMI >80th percentile59/21841.18 (0.83 to 1.69)1.21 (0.84 to 1.74)
BMI ≤80th percentile61/27710.92 (0.60 to 1.43)0.96 (0.62 to 1.48)
Treatment non-complianceBMI >80th percentile95/35311.40 (1.03 to 1.92)1.38 (1.00 to 1.89)
BMI ≤80th percentile†96/50101.00 (reference)1.00 (reference)
  • *After accounting for age, sex, ethnicity, income, user type, global assessment of severity score, number of exacerbations in previous year, exposure to smoke, asthma-related comorbidities, triggers, % predicted FEV1, ICS rescue use and season.

  • †Reference category.

  • BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.